Tiziana Life Sciences Ltd
TLSAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and. With a market capitalization of $129.8M, it sits in micro-cap territory. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Market Cap
$129.8M
Beta
0.45
P/E (TTM)
—
P/E (Fwd)
-5.11
EPS (TTM)
$-0.16
EPS (Fwd)
$-0.20
ROE
-924.3%
ROA
-116.0%
Cash
$4.0M
Total Debt
$456,000
Free CF
-$5.5M
52W Change
-44.9%
Annual Financials
Cash vs Debt
Where TLSA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TLSA finished 25.60% below its 150-day moving average ($1.25) and 30.60% below its 200-day moving average ($1.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLSA overbought or oversold?
At the September 3, 2026 close, TLSA's RSI(14) was 38.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tiziana Life Sciences Ltd holds $4.0M in cash against $456K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$5.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -924.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
TLSA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tiziana Life Sciences Ltd and its sector.